Literature DB >> 25384461

Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.

Alex Iranzo1, Heike Stockner, Mónica Serradell, Klaus Seppi, Francesc Valldeoriola, Birgit Frauscher, José Luis Molinuevo, Isabel Vilaseca, Thomas Mitterling, Carles Gaig, Dolores Vilas, Joan Santamaria, Birgit Högl, Eduard Tolosa, Werner Poewe.   

Abstract

Hyperechogenicity of the substantia nigra visualized by transcranial sonography occurs in most Parkinson's disease (PD) patients. Idiopathic rapid eye movement (REM) sleep behavior disorder (IRBD) subjects eventually develop PD and other synucleinopathies. This study was undertaken to evaluate whether in IRBD, transcranial sonography identifies subjects who convert to PD and other synucleinopathies, and whether substantia nigra echogenic size changes with time. It was a prospective study in which 55 IRBD patients underwent transcranial sonography at baseline and were invited to follow-up after 5 years. Patients were assessed by the same experienced sonographer who was blinded to clinical data and baseline transcranial sonography results, and used the same equipment and adjustments. Twenty-one (38.2%) subjects were diagnosed with a synucleinopathy (PD in 11, dementia with Lewy bodies in nine, and multiple system atrophy in one). Sensitivity of baseline substantia nigra hyperechogenicity for the development of a synucleinopathy was 42.1%, specificity 67.7%, positive predictive value 44.4%, negative predictive value 65.6%, and relative risk 1.29. No differences were detected between the first and second examination in mean size of the substantia nigra (0.20 ± 0.09 cm(2) vs. 0.19 ± 0.07 cm(2) ; P = 0.777) and in percentage of patients with substantia nigra hyperechogenicity (33.3% vs. 42.8%, P = 0.125). Transcranial sonography of the substantia nigra alone is not a useful tool to identify IRBD subjects at risk for the development of PD or a synucleinopathy after 5 years of follow-up. In IRBD, transcranial sonography cannot be used to monitor the degenerative process in the substantia nigra, because echogenicity size remains stable over time.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; REM sleep behavior disorder; follow-up; substantia nigra echogenicity; transcranial sonography

Mesh:

Year:  2014        PMID: 25384461     DOI: 10.1002/mds.26055

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  24 in total

Review 1.  Premotor Diagnosis of Parkinson's Disease.

Authors:  Heinz Reichmann
Journal:  Neurosci Bull       Date:  2017-08-03       Impact factor: 5.203

Review 2.  Clinical Significance of REM Sleep Behavior Disorders and Other Non-motor Symptoms of Parkinsonism.

Authors:  Hong Jin; Jin-Ru Zhang; Yun Shen; Chun-Feng Liu
Journal:  Neurosci Bull       Date:  2017-08-03       Impact factor: 5.203

Review 3.  Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies.

Authors:  Daniel A Barone; Claire Henchcliffe
Journal:  Clin Neurophysiol       Date:  2018-05-29       Impact factor: 3.708

Review 4.  Idiopathic REM sleep behaviour disorder and neurodegeneration - an update.

Authors:  Birgit Högl; Ambra Stefani; Aleksandar Videnovic
Journal:  Nat Rev Neurol       Date:  2017-11-24       Impact factor: 42.937

5.  What the "man in the moon" can tell us about the future of our brains.

Authors:  Birgit Högl
Journal:  Ann Transl Med       Date:  2017-09

6.  Brainstem raphe and substantia nigra echogenicity in idiopathic REM sleep behavior disorder with comorbid depression.

Authors:  Dolores Vilas; Alex Iranzo; Claustre Pont-Sunyer; Mónica Serradell; Carles Gaig; Joan Santamaria; Eduardo Tolosa
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

Review 7.  Clinical trials in REM sleep behavioural disorder: challenges and opportunities.

Authors:  Aleksandar Videnovic; Yo-El S Ju; Isabelle Arnulf; Valérie Cochen-De Cock; Birgit Högl; Dieter Kunz; Federica Provini; Pietro-Luca Ratti; Mya C Schiess; Carlos H Schenck; Claudia Trenkwalder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-05-13       Impact factor: 10.154

Review 8.  A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.

Authors:  Lama M Chahine; Amy W Amara; Aleksandar Videnovic
Journal:  Sleep Med Rev       Date:  2016-08-31       Impact factor: 11.609

Review 9.  Advances in markers of prodromal Parkinson disease.

Authors:  Ronald B Postuma; Daniela Berg
Journal:  Nat Rev Neurol       Date:  2016-10-27       Impact factor: 42.937

Review 10.  Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?

Authors:  Weidong Le; Jie Dong; Song Li; Amos D Korczyn
Journal:  Neurosci Bull       Date:  2017-09-02       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.